Inhaled mometasone raised a key marker of sickle cell disease severity by 42% compared with placebo in a 48-week trial of adults without asthma.
The single-center study, published November 2 in JAMA Network Open, found that soluble vascular cell adhesion molecule-1 (VCAM-1) levels rose significantly in the treatment arm by week 16. Healthcare utilization — including emergency department visits, hospital admissions, and acute chest syndrome episodes — trended higher in the mometasone group, though the differences did not reach statistical significance.
“These results suggest that long-term inhaled mometasone may not be effective for symptom management in sickle cell disease patients with episodic cough and wheeze who do not have asthma,” the study authors wrote.
VCAM-1 trajectory diverged from earlier trial
The phase 2 trial enrolled 77 adults with sickle cell disease (HbSS or HbSβ⁰) and episodic cough and wheeze but no asthma diagnosis. Participants, all on maximum tolerated hydroxyurea, were randomized to 220 μg of inhaled mometasone furoate daily or a matching placebo from December 2018 through May 2022.
The primary endpoint was percentage change in soluble VCAM-1 from baseline to week 48. In the mometasone group, VCAM-1 increased 42% relative to placebo (95% CI, 7.2%–85.5%; P = 0.01). A post-hoc analysis showed no difference at week 8, but by week 16 the mometasone arm had a 3.6% rise versus a 16.1% decline in the placebo arm (P = 0.02).
Intracellular adhesion molecule-3 (ICAM-3) also rose 0.23% more in the treatment group (95% CI, 0.019%–0.45%; P = 0.02). Markers of hemolysis — plasma-free hemoglobin, lactate dehydrogenase, total bilirubin, and reticulocyte count — did not differ between arms.
Clinical outcomes favored placebo numerically
Rate ratios for healthcare use consistently favored placebo, though confidence intervals were wide. Emergency department visits carried a rate ratio of 1.59 (95% CI, 0.81–3.12); acute pain visits, 1.71 (95% CI, 0.64–4.56); hospital admissions, 1.21 (95% CI, 0.52–2.81); and intensive care unit admissions, 2.18 (95% CI, 0.20–24.03).
Acute chest syndrome occurred in five patients (eight episodes) on mometasone and three patients (four episodes) on placebo, yielding a rate ratio of 4.27 (95% CI, 0.82–22.38; P = 0.09). Serious adverse events totaled 15 in the mometasone arm versus 11 in the placebo arm. No deaths were reported.
The trial was not powered to detect differences in clinical outcomes, and spirometry and sputum collection were halted during the COVID-19 pandemic, limiting respiratory endpoints.
Contrast with 15-week data raises mechanistic questions
A prior 15-week trial of inhaled mometasone in a similar population reported reduced VCAM-1 and improved daily pain scores. The current study’s lead author, Susanna A. Curtis, of the Icahn School of Medicine at Mount Sinai, and colleagues noted that the divergent VCAM-1 trajectory after week 16 warrants further investigation.
Mometasone furoate and placebo inhalers were provided by Merck Sharp & Dohme, which had no role in design, conduct, or analysis.
Do adults with sickle cell disease and episodic cough or wheeze but no asthma benefit from inhaled corticosteroids?
Current evidence from this 48-week randomized trial does not support routine use. VCAM-1, a validated severity biomarker, increased significantly with mometasone, and clinical event rates trended worse.
What is VCAM-1 and why does it matter in sickle cell disease?
Soluble vascular cell adhesion molecule-1 is an endothelial activation marker that correlates with vaso-occlusive pain frequency and acute chest syndrome risk. Rising levels signal greater endothelial dysfunction and disease severity.
How does this trial differ from the earlier 15-week study?
The earlier trial showed mometasone lowered VCAM-1 and improved pain over 15 weeks. This larger, longer trial found the opposite VCAM-1 trajectory after week 16 and no clinical benefit, highlighting a potential time-dependent harm not captured in shorter exposures.
Keep reading